Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE versus PHENERGAN VC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE versus PHENERGAN VC.
FEXOFENADINE HYDROCHLORIDE vs PHENERGAN VC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective peripheral H1-receptor antagonist; inhibits histamine release from mast cells and basophils, reducing allergic symptoms without significant central nervous system penetration.
Phenergan VC is a combination of promethazine (a phenothiazine derivative with antihistaminic, sedative, antiemetic, and anticholinergic effects) and phenylephrine (a sympathomimetic amine that acts as a decongestant via alpha-1 adrenergic receptor agonism). Promethazine antagonizes H1 receptors, thereby suppressing allergic reactions and motion sickness. Phenylephrine causes vasoconstriction in the nasal mucosa, reducing congestion.
60 mg orally twice daily or 180 mg orally once daily; maximum 180 mg/day.
10-20 mL orally every 4-6 hours as needed; each 5 mL contains 6.25 mg promethazine HCl and 5 mg phenylephrine HCl.
None Documented
None Documented
14.4 hours in healthy adults; prolonged in renal impairment (up to 58 hours in end-stage renal disease) requiring dose adjustment.
9-16 hours; prolonged in hepatic impairment.
Primarily fecal (80%) with approximately 11% renal excretion of unchanged drug. Biliary excretion contributes to fecal elimination.
Renal: 70-80% as metabolites; biliary/fecal: 20-30%.
Category A/B
Category C
Antihistamine
Antihistamine/Decongestant Combination